Coordinator Assistant
Resume:
sp
cialist
Jennifer
Fleets
–
Callan
Avenue,
Evanston,
IL
60202
T:
219-
929-
8459
F:
888-
241-
0122
E:
ab83zq@r.postjobfree.com
research
personal
statement
I
am
an
experienced
and
fully
certified
clinical
research
coordinator
who
is
efficient,
thorough
and
passionate
about
delivering
the
highest
quality
of
scientific
outcomes
for
purposes
of
medical
advancement.
I
possess
extensive
pharmaceutical
knowledge
in
key
areas
of
healthcare
including
neurology
and
cardiology.
I
am
highly
driven,
striving
to
progress
in
this
amazing
field
and
am
now
looking
for
a
suitable
position
with
a
reputable
company
to
pursue
new
and
exciting
endeavours.
professional
experience
Consultants
In
Cardiovascular
Medicine
–
Melrose
Park,
IL
CLINICAL
RESEARCH
COORDINATOR
March
2012
–
Present
• Responsible
for
the
coordination,
execution
and
management
of
more
than
15
cardiovascular
clinical
research
trials
• Develop
and
maintain
accurate
source
documentation
and
subject
case
reports
• Manage
all
study
duties
including
subject
consent,
vitals,
phlebotomy,
ECGs,
specimen
processing,
shipment,
tracking,
and
inventory
• Implement
the
recruitment,
informed
consent
and
retention
of
all
trial
subjects
• Execute
protocol
requirements
in
accordance
with
FDA
guidelines,
Good
Clinical
Practices
and
company
standard
operating
procedures
• Gained
recognition
for
being
the
primary
coordinator
of
the
highest
enrolling
site,
including
recruitment
of
minority
subjects,
for
the
Brigham
and
Women’s
Pre-
Determine
Trial
Ingenix-
i3
Research
–
Remote
Based
ASSESSMENT
SPECIALIST
January
2008
–
June
2008
• Assisted
and
trained
research
sites
for
certification
regarding
cognitive
scales
in
compliance
with
protocols
for
Phase
II
drug
studies
• Tracked
rater
training
progress
and
set
up
Central
Monitoring
of
cognitive
data
• Reviewed
and
edited
study
protocol
drafts
for
grammatical
accuracy
prior
to
final
release
Rush
University
Medical
Center
–
Chicago,
IL
ASSISTANT
STUDY
COORDINATOR
March
2006
–
December
2007
• Certified
psychometrist
responsible
for
administering
a
battery
of
cognitive
tests
for
over
10
different
Alzheimer’s
disease
studies
for
patient
neuropsychological
evaluation
and
clinical
diagnostic
purposes
including
the
Memory
and
Aging
Project
and
the
Religious
Orders
Study
• Managed
all
study
specimen
collection
duties
including
patient
vitals,
phlebotomy,
ECGs,
lumbar
puncture
assistance,
processing,
shipment,
tracking,
and
general
lab
maintenance
and
inventory
• Developed
and
implemented
new
protocols
for
clinic
and
research
staff
to
enhance
and
improve
patient
evaluation
services
•
areas
of
expertise
CRF
Development
Event
Reporting
IVRS
/
IWRS
Experience
Regulatory
Compliance
Data
Analysis
&
Cleaning
Internal
Auditing
Minority
Recruitment
&
Retention
Source
Documentation
Electronic
Data
Capture
IP
Accountability
Pharmaceuticals
/
Pharmacokinetics
Spanish
Speaking
EMR
Implementation
IRB
Submissions
Protocol
Comprehension
&
Execution
Subject
Screening
&
Selection
academic
qualifications
relative
occupational
experience
Purdue
University
-
1999
-
2005
-
School
of
Pharmacy-
B.S.
Pharmaceutical
Sciences
American
Red
Cross
–
phlebotomist
Purdue
University
-
1999
-
2005
-
School
of
Science-
B.S.
Biology
July
2011
–
March
2012
Purdue
University
-
1999
–
2005
-
Minor-
Psychology
CSL
Plasma
–
Training
and
professional
memberships
Development
Coordinator
November
2010
–
March
2011
Society
of
Clinical
Research
Associates
RPh
C
all,
L
On
LC.
Association
of
Clinical
Research
Professionals
Pharmacy
T
echnician
American
Management
Association
August
2
009
–
A
ugust
2
010
American
Heart
Association
Alzheimer’s
Association
International
Society
to
Advance
Alzheimer’s
Research
and
Treatment
Freelance
Professional
Writing/Editing
1999-
present
publications
Amanda
R.
Bolbecker,
Corrinne
C.
M.
Lim-
Kessler,
Jia
Li,
Alicia
Swan,
Adrienne
Lewis,
Jennifer
Fleets,
and
Gerald
S.
Wasserman.
Visual
Efference
Neuromodulates
Retinal
Timing:
In
Vivo
Roles
of
Octopamine,
Substance
P,
Circadian
Phase,
and
Efferent
Activation
in
Limulus.
Journal
of
Neurophysiology-
102:1132-
1138,
2009.
Amanda
R.
Bolbecker,
Adrienne
R.
Lewis,
Alicia
A.
Swan,
Kenneth
Carlson,
Jennifer
R.
Fleets,
Kathryn
E.
Beck,
Gerald
S.
Wasserman.
Stable
bellows
cup
electrode
demonstrates
low-
frequency
properties
of
long-
term
electroretinographic
recordings
in
the
Limulus
lateral
eye.
Journal
of
Neuroscience
Methods-
159
(2007)
252-
260.
clinical
research
trials-
cardiology
A
Phase
3b
Study
To
Evaluate
The
Potential
Of
Aleglitazar
To
Reduce
Cardiovascular
Risk
In
Patients
With
Stable
Cardiovascular
•
Disease
And
Glucose
Abnormalities.
(AlePrevent).
F.
Hoffmann-
La
Roche.
Coordinator.
2013
–
Present.
A
Multicenter,
Randomized,
Double-
Blind,
Placebo-
Controlled
Study
Accessing
the
Occurrence
Of
Major
Adverse
Cardiovascular
•
Events
(MACE)
in
Overweight
and
Obese
Subjects
With
Cardiovascular
Risk
Factors
Receiving
Naltrexone
SR/Bupropion
SR.
(LIGHT
Study).
Orexigen
Therapeutics.
Coordinator.
2012
–
Present.
•
Evaluation
of
Varenicline
(Champix)
in
Smoking
Cessation
for
Patients
Post-
Acute
Coronary
Syndrome.
(EVITA
Trial).
•
McGill
University.
Coordinator.
2012
–
Present.
A
Phase
IV
Prospective,
Open
Label
Study
Evaluating
The
Efficacy
of
Two
Management
Strategies
(Pantoprazole
40
mg
q.a.m.
And
•
Taking
Pradaxa
With
Food
Within
30
Minutes
After
A
Meal)
On
Gastrointestinal
Symptoms
(GIS)
In
Patients
Newly
On
Treatment
With
Pradaxa
150
mg
b.i.d.
Or
75
mg
b.i.d.
For
The
Prevention
Of
Stroke
And
Systemic
Embolism
In
Patients
With
Non-
Valvular
Atrial
Fibrillation
(NVAF).
Boehringer
Ingelheim
Pharmaceuticals,
Inc.
Coordinator.
2012
–
Present.
Trial
To
Evaluate
Cardiovascular
Outcomes
After
Treatment
With
Stigaliptin
In
Patients
With
Type
2
Diabetes
Mellitus
And
•
Inadequate
Glycemic
Control.
(TECOS).
Merck
&
Co.,
Inc.
Coordinator.
2012
–
Present.
Global
Registry
On
Long-
Term
Oral
Anti-
thrombotic
Treatment
In
Patients
With
Atrial
Fibrillation.
(GLORIA
–
AF).
•
Boehringer
Ingelheim
Pharmaceuticals,
Inc.
Coordinator.
2012
–
Present.
Biomarkers
In
Sudden
Cardiovascular
Death.
(Pre-
Determine).
Brigham
And
Women’s
Hospital.
Coordinator.
2012
–
Present.
•
A
Randomized,
Double-
Blind,
Placebo
Controlled,
Parallel
Group,
Multinational
Trial,
To
Assess
The
Prevention
Of
Thrombotic
•
Events
With
Ticagrelor
Compared
To
Placebo
On
A
Background
Of
Acetyl
Salicylic
Acid
(ASA)
Therapy
In
Patients
With
History
Of
Myocardial
Infarction.
(PEGASUS).
AstraZeneca.
Coordinator.
2012
–
Present.
A
Multicenter,
Randomized,
Active-
Control,
Phase
IIIB
Study
To
Evaluate
The
Cardiovascular
Safety
Of
Febuxostat
And
Allopurinol
•
In
Subjects
With
Gout
And
Cardiovascular
Comorbidities.
(TMX-
67_301).
Takeda
Global
Research
&
Development
Center,
Inc.
Coordinator.
2012
–
Present.
A
Multicenter,
Randomized,
Double-
Blind,
Parallel
Group,
Active-
Controlled
Study
To
Evaluate
The
Efficacy
And
Safety
Of
LCZ696
•
Compared
to
Enalapril
On
Morbidity
and
Mortality
In
Patients
With
Chronic
Heart
Failure
And
Reduced
Ejection
Fraction.
(Paradigm).
Novartis
Pharmaceuticals.
Coordinator.
2012
–
Present.
A
Clinical
Outcomes
Study
of
Darapladib
Versus
Placebo
In
Subjects
Following
Acute
Coronary
Syndrome
To
Compare
The
•
Incidence
Of
Major
Adverse
Cardiovascular
Events.
(SOLID).
GlaxoSmith
Kline.
Coordinator.
2012
–
Present.
A
Randomized,
Placebo-
Controlled,
Double-
Blind,
Parallel
Group,
Multicenter,
Event
Driven
Trial
To
Stabilize
Atherosclerotic
•
Plaque
By
Initiating
Investigational
Product
Therapy
Versus
Placebo
In
Subjects
With
Chronic
Coronary
Heart
Disease
To
Compare
Incidence
of
Major
Adverse
Cardiovascular
Events.
(STABILITY)
GlaxoSmithKline.
Coordinator.
2012
–
Present.
Outcomes
Registry
for
Better
Informed
Treatment
of
Atrial
Fibrillation.
(ORBIT-
AF).
The
Duke
Clinical
Research
Institute
and
Ortho-
•
McNeil
Janssen
Scientific
Affairs,
LLC.
Coordinator.
2012
–
Present.
• A
Phase
III,
Randomized,
Double-
Blind,
Double-
Dummy,
Parallel
Group,
Multi-
Center,
Multi-
National
Study
For
The
Evaluation
Of
Efficacy
And
Safety
Of
Edoxaban
Versus
Warfarin
In
Subjects
With
Atrial
Fibrillation-
Effective
Anticoagulation
With
Factor
xA
Next
Generation
In
Atrial
Fibrillation.
(ENGAGE).
Daiichi
Sankyo
Pharma
Development.
Coordinator.
2012
–
Present.
• A
Phase
III,
Double-
Blind,
Randomized,
Placebo-
Controlled
Study,
To
Evaluate
The
Effects
Of
Dalcetrapib
On
Cardiovascular
Risk
In
Stable
CHD
Patients,
With
Documented
Recent
Acute
Coronary
Syndrome.
(ROCHE).
F.
Hoffmann-
La
Roche.
Coordinator.
2012
–
Present.
• A
Double-
Blind,
Randomized,
Placebo-
Controlled,
Multicenter
Study
To
Assess
The
Efficacy
And
Safety
Of
Darbepoetin
Treatment
On
Mortality
And
Morbidity
In
Heart
Failure
(HF)
Subjects
With
Symptomatic
Left
Ventricular
Systolic
Dysfunction
And
Anemia.
(RED-
HF).
Amgen.
Coordinator.
2012
-
Present.
• A
Multicenter,
Double-
Blind,
Randomized
Study
To
Establish
The
Clinical
Benefit
And
Safety
Of
Vytorin
(Ezetimibe/Simvastatin
Tablet)
Vs.
Simvastatin
Monotherapy
In
High-
Risk
Subjects
Presenting
With
Acute
Coronary
Syndrome
(IMProved
Reduction
of
Outcomes:
Vytorin
Efficacy
International
Trial
–
IMPROVE
IT).
Schering-
Plough
Research
Institute.
Coordinator.
2012
–
Present.
clinical
research
trials-
neuroscience
• A
Multi-
Center,
Randomized,
Double-
Blind,
Placebo-
Controlled
Trial
of
Simvastatin
to
Slow
the
Progression
of
Alzheimer’s
Disease.
National
Institute
On
Aging.
Assistant
Study
Coordinator
/
Psychometrist.
2006
–
2008.
• A
Multi-
Center,
Randomized,
Double-
Blind,
Placebo-
Controlled
Therapeutic
Trial
to
Determine
Whether
Natural
Huperzine
A
Improves
Cognitive
Function.
National
Institute
On
Aging.
Assistant
Study
Coordinator
/
Psychometrist.
2006
–
2008.
• Alzheimer’s
Disease
Neuroimaging
Initiative.
National
Institutes
of
Health.
Assistant
Study
Coordinator
/
Psychometrist.
2006
–
2008.
• A
Double-
Blind,
Phase
II,
Safety
and
Efficacy
Evaluation
of
ONO-
2506PO
in
Patients
with
Mild
to
Moderate
Alzheimer’s
Disease.
Ono
Pharmaceutical/Omnicare
Clinical
Research.
Assistant
Study
Coordinator
/
Psychometrist.
2006
–
2008.
• A
Multi-
Center,
Randomized,
Controlled
Clinical
Trial
to
Determine
Whether
Reduction
of
Homocysteine
Levels
with
High-
Dose
Folic
Acid/B6/B12
Supplementation
Will
Slow
the
Rate
of
Cognitive
Decline
In
Subjects
with
Alzheimer’s
Disease.
Alzheimer’s
Disease
Cooperative
Study
and
National
Institute
On
Aging.
Assistant
Study
Coordinator
/
Psychometrist.
2006
–
2008.
• Rush
University
Memory
and
Aging
Project-
A
Longitudinal,
Epidemiologic
Clinical-
Pathologic
Cohort
Study
of
Common
Chronic
Conditions
of
Aging
With
an
Emphasis
on
Decline
in
Cognitive
and
Motor
Function
and
Risk
of
Alzheimer's
Disease.
National
Institute
On
Aging.
Psychometrist.
2006
–
2008.
• Rush
University
Religious
Orders
Study-
A
Longitudinal
Clinical-
Pathologic
Cohort
Study
of
Aging
and
Alzheimer's
Disease.
National
Institute
On
Aging.
Psychometrist.
2006
–
2008.
• Minority
Aging
Research
Study
(MARS)-
A
Longitudinal,
Epidemiologic
Cohort
Study
of
Decline
in
Cognitive
Function
and
Risk
of
Alzheimer's
Disease
in
Older
African
Americans.
Psychometrist.
2006
–
2008.
references
Available
on
request.
Contact this candidate